No Data
Weilizhizhi is applying to list on the Hong Kong Stock Exchange, positioning itself as a leader in the development of next-generation tumor immunotherapy.
Currently, the heat and activity of the bispecific antibody track are rapidly rising, and it has become a new hot spot in the global innovative drugs industry. Multinational pharmaceutical companies are actively "sweeping the shelves", actively seeking and investing in promising bispecific pipelines. According to the statistics of Bioon, in the first three quarters of 2024, global pharmaceutical companies' transaction activities in the field of bispecific drugs were exceptionally active, with a total of 31 transactions completed. This number exceeds the total annual transaction volume of any year in the past three years, enough to show that the status and influence of bispecific drugs in the global pharmaceutical market are rapidly rising. Among them, there were 5 large BD transactions on bispecific/trispecific drugs in November alone, with high amounts involved.
Insider Sale: Director at $BGNE (BGNE) Sells 200 Shares
Bernstein Maintains BeiGene(BGNE.US) With Hold Rating, Raises Target Price to $207
Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
BeiGene's Four Drugs Included in China's Medical Insurance Catalog; Shares Jump 5%
Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE) and Teladoc (TDOC)
No Data
No Data
